2023

Received the Minister of Health
and Welfare Award

2022 - 2023

Production of drug substances and
drug products for the clinical phase II

2022

Approval of the clinical phase I from
MFDS in Korea

2021

Acquired the grant from a government Initiative

2020 - 2021

Production of drug substances and drug products for the clinical phase I

2019

Establishment of GMP production technology

2018

POSVAX established Establishment of MCB (Master Cell Bank)

2013

Securing core technology and applying for worldwide patent

2008 ~ 13

Development of Bivalent HPV vaccine
(Clinical phase I with a partner)

2004

Initiate development of VLP-based HPV vaccine